Interstitial Cystitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Interstitial Cystitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Interstitial Cystitis therapeutics.

Key Highlights

• In 2022, there will be more than one million diagnosed prevalent cases of IC across 16 pharmaceutical markets.
• There are four FDA approved branded marketed products available for the treatment of IC.
• The IC pipeline consists of over 16 pharmaceuticals spanning all stages of development, with seven molecules in Phase II and no molecules in late-stage development (Phase III or pre-registration).
• Commercial sponsors dominate clinical trial development in IC, with the US emerging as the key countries for conducting trials in IC.
• Deals involving acquisition of IC assets are the most common types of deals in the US and Asia-pacific.
• Companies are increasingly focusing on R&D activities to develop therapies to treat IC.

Scope

GlobalData’s Interstitial Cystitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Interstitial Cystitis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Interstitial Cystitis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.